Good
Mostly Aligned
Patient Risk:
Low
Summary
Only the BPH indication claim is supported by the provided FDA label excerpt (Indications and Usage). All other claims (pricing, insurance, patient assistance, patent/generic pricing) are absent from the provided label text and therefore cannot be verified against it.
Category Scores
Accurate Statements
Silodosin is a prescription medication used to treat the symptoms of benign prostatic hyperplasia (BPH).
Supported by label section 1 (INDICATIONS AND USAGE): 'RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).' (Label excerpt provided).
Unsupported Statements
Without insurance, a 30-day supply of silodosin 8 mg capsules can range from approximately $70 to $150 or more.
Not supported or mentioned in the provided label excerpt (only Indications and Usage provided).
Generic versions of silodosin are generally lower in price than brand-name formulations.
Not supported or mentioned in the provided label excerpt.
Generic silodosin 8 mg capsules might cost around $40 to $80 for a 30-day supply.
Not supported or mentioned in the provided label excerpt.
Most insurance plans offer coverage for silodosin.
Not supported or mentioned in the provided label excerpt.
Insurance can significantly reduce out-of-pocket costs for silodosin.
Not supported or mentioned in the provided label excerpt.
Copays for silodosin typically range from $10 to $50 depending on the specific insurance plan and whether the prescription is for a brand-name or generic version.
Not supported or mentioned in the provided label excerpt.
Some insurance plans may require prior authorization for silodosin.
Not supported or mentioned in the provided label excerpt.
Some insurance plans may have specific pharmacy networks.
Not supported or mentioned in the provided label excerpt.
Pharmaceutical manufacturers may provide patient assistance programs or discount cards that can lower the cost of prescription medications.
Not supported or mentioned in the provided label excerpt.
Patient assistance programs or discount cards may offer savings of 25% to 75% off the retail price for eligible individuals.
Not supported or mentioned in the provided label excerpt.
Online pharmacies and coupon websites can list available discounts and compare prices from different retailers.
Not supported or mentioned in the provided label excerpt.
The price of silodosin is influenced by manufacturing costs, research and development expenses, market demand, and competition.
Not supported or mentioned in the provided label excerpt.
The price of silodosin can also be affected by supply chain dynamics and pharmacy dispensing fees.
Not supported or mentioned in the provided label excerpt.
The patent expiration date for silodosin is a key factor in the availability and pricing of generic versions.
Not supported or mentioned in the provided label excerpt.
The original patents for silodosin have expired, which has allowed for the introduction of generic alternatives.
Not supported or mentioned in the provided label excerpt.
Competition from generic alternatives generally leads to lower prices for consumers.
Not supported or mentioned in the provided label excerpt.
Generic silodosin is typically much less expensive than the brand-name version.
Not supported or mentioned in the provided label excerpt.
Generic silodosin often costs 50% to 85% less than the brand-name version.
Not supported or mentioned in the provided label excerpt.
The price difference between generic and brand-name silodosin is due to the absence of research and development costs incurred by the original manufacturer.
Not supported or mentioned in the provided label excerpt.
Contradictions
Important Omissions
No label-supported dosage and administration, contraindications, warnings/precautions, drug interactions, adverse reactions, monitoring, or storage/handling information could be evaluated because the prompt provided only label section 1 (INDICATIONS AND USAGE).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only on-label claim provided is the indication (BPH treatment). Pricing/insurance/patent statements are not addressed in the provided label excerpt; they are not label-supported but also not directly dosing/safety guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Most claims are not verifiable against the provided FDA label excerpt because they concern pricing, insurance coverage, patient assistance, and patents, which are absent from the supplied labeling text.
Suggested Improvement
Limit claims to on-label content present in the provided label section (e.g., indication for BPH) or supply additional FDA label sections if evaluating dosing, contraindications, warnings, interactions, or safety information.